Bellingham Retina Specialists, PLLC
Bellingham Retina Specialists, PLLC was paid $1.45M by Medicaid between Jan 2018 and Oct 2024, across 25 billing codes. Its largest line is J2777, Injection, faricimab-svoa, 0.1 mg — 21% of everything it billed.
33Billing provider infoBELLINGHAM RETINA SPECIALISTS, PLLC
BELLINGHAM, WA 98226
BELLINGHAM, WA 98226
33aNPI1659600443assigned 12/08/2009
33bProvider typeSpecialist
28Total paid$1.45M
24GClaims30,062
24DCodes billed25
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other Specialist providers in Washington
Rank by total paid#10 of 96
Median peer was paid$49K
This provider vs. median30×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,957 | $112K | |
| 2019 | 5,102 | $123K | |
| 2020 | 3,250 | $112K | |
| 2021 | 4,047 | $326K | |
| 2022 | 4,381 | $359K | |
| 2023 | 3,674 | $232K | |
| 2024incomplete | 2,651 | $188K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | 21% | 343 | 208 | $309K |
| J0178 | Injection, aflibercept, 1 mg | 20% | 293 | 205 | $292K |
| J2778 | Injection, ranibizumab, 0.1 mg | 15% | 540 | 292 | $221K |
| 67028 | Intravitreal injection of a pharmacologic agent | 12% | 4,958 | 4,446 | $171K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 8.5% | 4,763 | 4,368 | $124K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 5.6% | 2,305 | 2,204 | $81K |
| 92134 | 4.8% | 5,729 | 5,248 | $69K | |
| 92250 | 4.0% | 3,847 | 3,519 | $58K | |
| J9035 | Injection, bevacizumab, 10 mg | 3.2% | 1,067 | 642 | $47K |
| 92235 | 2.2% | 949 | 918 | $31K | |
| J3590 | Unclassified biologics | <1% | 50 | 31 | $14K |
| 92226 | <1% | 1,757 | 1,198 | $14K |
13 more codes
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 215 | $13K |
| 92202 | <1% | 1,035 | $5K | |
| 92225 | <1% | 171 | $1K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 41 | $852.93 |
| G9744 | Patient not eligible due to active diagnosis of hypertension | 0% | 389 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 115 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 602 | $0.00 |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | 0% | 55 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 27 | $0.00 |
| G8952 | Elevated or hypertensive blood pressure reading documented, indicated follow-up not documented, reason not given | 0% | 40 | $0.00 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 155 | $0.00 |
| 1036F | 0% | 401 | $0.00 | |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 215 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHASSLER, JULIA (OFFICE MANAGER)